|
1
|
Zhu Z, Shen Z and Xu C: Inflammatory
pathways as promising targets to increase chemotherapy response in
bladder cancer. Mediators Inflamm. 2012:5286902012.PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kusenda B, Mraz M, Mayer J and Pospisilova
S: MicroRNA biogenesis, functionality and cancer relevance. Biomed
Pap Med Fac Univ Palacky Olomouc Czech Repub. 150:205–215. 2006.
View Article : Google Scholar
|
|
7
|
Mraz M, Pospisilova S, Malinova K, Slapak
I and Mayer J: MicroRNAs in chronic lymphocytic leukemia
pathogenesis and disease subtypes. Leuk Lymphoma. 50:506–509. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cohen JE, Lee PR and Fields RD: Systematic
identification of 3′-UTR regulatory elements in activity-dependent
mRNA stability in hippocampal neurons. Philos Trans R Soc Lond B
Biol Sci. 369:201305092014. View Article : Google Scholar
|
|
9
|
Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato
JM and Lu SC: MicroRNAs regulate methionine adenosyltransferase 1A
expression in hepatocellular carcinoma. J Clin Invest. 123:285–298.
2013. View
Article : Google Scholar :
|
|
10
|
Costa FF, Bischof JM, Vanin EF, Lulla RR,
Wang M, Sredni ST, Rajaram V, Bonaldo MF, Wang D, Goldman S, et al:
Identification of microRNAs as potential prognostic markers in
ependymoma. PLoS One. 6:e251142011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Formosa A, Markert EK, Lena AM, Italiano
D, Finazzi-Agro' E, Levine AJ, Bernardini S, Garabadgiu AV, Melino
G and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c,
miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p,
mapped to the 14q32.31 locus, regulate proliferation, apoptosis,
migration and invasion in metastatic prostate cancer cells.
Oncogene. 33:5173–5182. 2014. View Article : Google Scholar
|
|
12
|
Anaya-Ruiz M, Bandala C and Perez-Santos
JL: miR-485 acts as a tumor suppressor by inhibiting cell growth
and migration in breast carcinoma T47D cells. Asian Pac J Cancer
Prev. 14:3757–3760. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Catto JW, Alcaraz A, Bjartell AS, De Vere
White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L,
Schlomm T and Visakorpi T: MicroRNA in prostate, bladder, and
kidney cancer: a systematic review. Eur Urol. 59:671–681. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gits CM, van Kuijk PF, de Rijck JC,
Muskens N, Jonkers MB, van IJcken WF, Mathijssen RH, Verweij J,
Sleijfer S and Wiemer EA: MicroRNA response to hypoxic stress in
soft tissue sarcoma cells: microRNA mediated regulation of HIF3α.
BMC Cancer. 14:4292014. View Article : Google Scholar
|
|
15
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brabletz T, Hlubek F, Spaderna S,
Schmalhofer O, Hiendlmeyer E, Jung A and Kirchner T: Invasion and
metastasis in colorectal cancer: epithelial-mesenchymal transition,
mesenchymal-epithelial transition, stem cells and beta-catenin.
Cells Tissues Organs. 179:56–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Di Cello F, Hillion J, Hristov A, Wood LJ,
Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R
and Resar LM: HMGA2 participates in transformation in human lung
cancer. Mol Cancer Res. 6:743–750. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lanahan A, Williams JB, Sanders LK and
Nathans D: Growth factor-induced delayed early response genes. Mol
Cell Biol. 12:3919–3929. 1992.PubMed/NCBI
|
|
19
|
Narita M, Narita M, Krizhanovsky V, Nuñez
S, Chicas A, Hearn SA, Myers MP and Lowe SW: A novel role for
high-mobility group a proteins in cellular senescence and
heterochromatin formation. Cell. 126:503–514. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gattas GJ, Quade BJ, Nowak RA and Morton
CC: HMGIC expression in human adult and fetal tissues and in
uterine leiomyomata. Genes Chromosomes Cancer. 25:316–322. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou X, Benson KF, Ashar HR and Chada K:
Mutation responsible for the mouse pygmy phenotype in the
developmentally regulated factor HMGI-C. Nature. 376:771–774. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ashar HR, Chouinard RA Jr, Dokur M and
Chada K: In vivo modulation of HMGA2 expression. Biochim Biophys
Acta. 1799:55–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pfannkuche K, Summer H, Li O, Hescheler J
and Dröge P: The high mobility group protein HMGA2: A co-regulator
of chromatin structure and pluripotency in stem cells? Stem Cell
Rev. 5:224–230. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Piscuoglio S, Zlobec I, Pallante P, Sepe
R, Esposito F, Zimmermann A, Diamantis I, Terracciano L, Fusco A
and Karamitopoulou E: HMGA1 and HMGA2 protein expression correlates
with advanced tumour grade and lymph node metastasis in pancreatic
adenocarcinoma. Histopathology. 60:397–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Y, Song Y and Liu H: Expression and its
clinical significance of HMGA2 in the patients with non-small cell
lung cancer. Zhongguo Fei Ai Za Zhi. 11:377–381. 2008.In Chinese.
PubMed/NCBI
|
|
26
|
Langelotz C, Schmid P, Jakob C, Heider U,
Wernecke KD, Possinger K and Sezer O: Expression of
high-mobility-group-protein HMGI-C mRNA in the peripheral blood is
an independent poor prognostic indicator for survival in metastatic
breast cancer. Br J Cancer. 88:1406–1410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Malek A, Bakhidze E, Noske A, Sers C,
Aigner A, Schäfer R and Tchernitsa O: HMGA2 gene is a promising
target for ovarian cancer silencing therapy. Int J Cancer.
123:348–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Liu X, Li AY, Chen L, Lai L, Lin
HH, Hu S, Yao L, Peng J, Loera S, et al: Overexpression of HMGA2
promotes metastasis and impacts survival of colorectal cancers.
Clin Cancer Res. 17:2570–2580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang GL, Zhang LH, Bo JJ, Hou KL, Cai X,
Chen YY, Li H, Liu DM and Huang YR: Overexpression of HMGA2 in
bladder cancer and its association with clinicopathologic features
and prognosis HMGA2 as a prognostic marker of bladder cancer. Eur J
Surg Oncol. 37:265–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding X, Wang Y, Ma X, Guo H, Yan X, Chi Q,
Li J, Hou Y and Wang C: Expression of HMGA2 in bladder cancer and
its association with epithelial-to-mesenchymal transition. Cell
Prolif. 47:146–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
